Cutaneous Lupus Erythematosus (CLE)
Cutaneous lupus erythematosus (CLE) is an autoimmune condition with diverse manifestations, ranging from exclusive skin involvement to being one of several presentations of systemic lupus erythematosus. An improved understanding of CLE's pathogenesis could aid in developing more precise therapeutic strategies. With our company, you gain access to a seasoned and specialized team committed to tackling drug and therapy development challenges specific to CLE.
Introduction to CLE
CLE is a chronic autoimmune skin disease characterized by inflammation and lesions on the skin. It is a subtype of lupus erythematosus, an autoimmune condition that can affect various organs and tissues in the body. CLE primarily affects the skin, leading to symptoms such as rashes, redness, and scarring. Estimates suggest that the prevalence of CLE ranges from approximately 20 to 70 cases per million people.
Pathogenesis of CLE
The pathogenesis of CLE involves various factors, including genetic predisposition, immune dysregulation, and environmental triggers.
Genetic Factors
Genetic factors play a significant role in the development of CLE, with certain gene variants associated with susceptibility to the condition.
Immune Dysregulation
Activation of T cells and B cells in the immune system leads to the production of autoantibodies that target skin tissues, causing inflammation and damage.
Environmental Factors
Environmental factors, like exposure to ultraviolet radiation, infections, and drug exposure can trigger abnormal activation of the immune system, exacerbating the severity of CLE.
Fig.1 Overview of cutaneous lupus erythematosus subtypes and schematic illustration of pathogenic mechanisms in CLE. (Niebel, D., et al., 2023)Diagnostics Development of CLE
The progression in diagnostics for CLE encompasses evaluation, the analysis of skin biopsy histopathology, and laboratory testing to identify characteristic skin manifestations and immunological abnormalities associated with the disease. Laboratory includes antinuclear antibody (ANA) testing, anti-double-stranded DNA (anti-dsDNA) antibody testing, and other autoantibody assays to detect specific autoantibodies commonly found in CLE individuals.
Therapy Development of CLE
Monoclonal antibody therapies represent a promising avenue for treating CLE by targeting specific molecules involved in the pathogenesis of the disease. Examples include belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator (BLyS), and ustekinumab, which targets interleukin-12 (IL-12) and interleukin-23 (IL-23) cytokines.
Mesenchymal stem cells (MSCs) possess immunomodulatory properties and can regulate the activity of immune cells, thereby suppressing inflammation and promoting tissue regeneration. Advancements in cell engineering technologies, such as gene editing and CAR-T cell therapy, hold potential for the development of targeted and personalized cell-based Therapy for CLE.
Our Services
Our company is committed to delivering thorough product development solutions tailored to CLE. We ensure streamlined and expeditious product development processes by identifying objectives and areas for enhancement and asking relevant questions.
Platforms of CLE Therapy Development
Animal Models of CLE
We have established expertise in developing and utilizing relevant animal models that closely mimic the disease characteristics and response to therapy. These models enable us to evaluate the safety and efficacy of potential therapies.
| Non-Genetically Engineering Models | ||
|---|---|---|
| Our organization specializes in delivering top-notch services for creating NON-GEMs, providing diverse model choices customized to meet specific research needs related to CLE. | ||
| Optional Models |
|
|
| Genetically Engineered Models | ||
| Our expertise in genetic engineering techniques, such as CRISPR/Cas9 technology, allows us to generate accurate and reliable models that recapitulate the genetic alterations observed in human CLE. | ||
| Optional Models |
|
|
| Optional Species | Mice, Rats, Others | |
In addition to these models, our comprehensive services encompass other models that target specific signaling pathways and molecular targets. These models have provided valuable insights into the pathogenesis of CLE and identify potential therapeutic targets and strategies.
If our services resonate with your needs, please feel free to get in touch and contact us whenever it suits your schedule. We're ready to discuss how we can tailor our solutions to fit seamlessly with your objectives and support your success.
References
- Niebel, D., et al., "Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions." Am J Clin Dermatol (2023). 24(4): p. 521-540.
- Vale, E. and Garcia, L.C., "Cutaneous lupus erythematosus: a review of etiopathogenic, diagnostic and therapeutic aspects." An Bras Dermatol (2023). 98(3): p. 355-372.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
